Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2010 on NSE
Last close ₹893.40up ₹28.40 (3.28%)BSE ₹891.95
Share price at the NSE close on 29 Oct 2026. Previous close ₹865.00.
29 Oct: open ₹868.30, high ₹897.40, low ₹860.20
52-week range of traded prices to 29 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,350 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 44,68549.6% delivered
Orchid Pharma board meetings
137 filed, newest first. Page 3 of 3.
May 2014
Jan 2014
Dec 2013
Nov 2013
Aug 2013
6 Aug · Board meeting
To take on record the unaudited financial results of the Company for the period from April 01, 2013 to June 30, 2013, Q5 of the extended financial year 2012-2013.
May 2013
Apr 2013
18 Apr · Board meeting
Feb 2013
Oct 2012
26 Oct · Board meeting
Inter alia to consider and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2012.
Aug 2012
6 Aug · Board meeting
Inter-alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2012.
May 2012
4 May · Board meeting
To :- (1) Approve the audited financial results of the Company for the financial year ended March 31, 2012; (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2012.
Jan 2012
25 Jan · Board meeting
To take on record the unaudited financial results of orchid for the period from October 01, 2011 to December 31, 2011.7 Jan · Board meeting
Board of Directors of the Company at their meeting held on January 07, 2012, inter-alia has approved a Scheme of Amalgamation ('the Scheme') for merger of company's wholly owned subsidiary viz. Orchid Research Laboratories Limited ('the transferor company') with Orchid under the provisions of Sections 391 to 394 of the Companies Act, 1956. The Appointed date of the Amalgamation is April 01, 2010 and the Scheme is subject to the approval of The Hon'ble High Court of Madras. The transferor company being a wholly owned subsidiary no fresh shares will be issued by the Company upon the Scheme coming into effect.
Dec 2011
28 Dec · Board meeting
To consider the proposal for merger of its wholly owned subsidiary, Orchid Research Laboratories Ltd with Orchid Chemicals & Pharmaceuticals Ltd.
Oct 2011
20 Oct · Board meeting
To take on record the Unaudited Financial Results of Orchid for period from July 01, 2011 to September 30, 2011.
Jul 2011
18 Jul · Board meeting
To take on record the unaudited financial results of the Company for the period from April 01, 2011 to June 30, 2011.
May 2011
4 May · Board meeting
To :- (1) Approve the audited financial results of the Company for the financial year ended March 31, 2011; (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2011.
Jan 2011
7 Jan · Board meeting
To take on record the unaudited financial results of Orchid for the period from October 1,2010 to December 31,2010.
Oct 2010
15 Oct · Board meeting
To take on record the unaudited financial results of the Company for the period from July 01, 2010 to September 30, 2010.
Jul 2010
12 Jul · Board meeting
To take on record the unaudited financial results of Orchid for the period from April 01, 2010 to June 30, 2010.
May 2010
18 May · Board meeting
(1) Approve the audited financial results of the Company for the financial year ended March 31, 2010; (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2010.
Jan 2010
19 Jan · Board meeting
To take on record the unaudited financial results of Orchid for the period from October 01, 2009 to December 31, 2009.
Oct 2009
20 Oct · Board meeting
To take on record the unaudited financial results of Orchid for the period from July 01, 2009 to September 30, 2009.
Jul 2009
21 Jul · Board meeting
To take on record the unaudited financial results of Orchid for the period from April 1, 2009 to June 30, 2009.
Jun 2009
18 Jun · Board meeting
To: - (1) Approve the audited financial results of the Company for the financial year ended March 31, 2009. (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2009.
Jan 2009
20 Jan · Board meeting
Meeting on 28 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
21 Oct · Board meeting
Meeting on 30 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
22 Jul · Board meeting
Meeting on 30 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
May 2008
21 May · Board meeting
To approve the audited financial results of the Company for the financial year ended March 31, 2008. Consider recommendation of dividend on equity capital for the financial year ended March 31, 2008.
Jan 2008
7 Jan · Board meeting
To take on record the un-audited financial results of the Company for the period from October 01, 2007 to December 31, 2007.
Oct 2007
8 Oct · Board meeting
To take on record the Un-audited financial results for the period from July 01, 2007 to September 30, 2007.
Jul 2007
11 Jul · Board meeting
Meeting on 19 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Apr 2007
25 Apr · Board meeting
(1) Adopt the audited financial results of Orchid for the financial year ended March 31, 2007. (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2007.
Jan 2007
22 Jan · Board meeting
That the following has been considered at a meeting of the Board of Directors of the Company held on Friday, January 19, 2007:- (a) Issue of Warrants - Issue of 5 million Warrants, convertible into Equity Share to the Promoter(s)/Promoter Group(s)/Relatives of Prmoters in accordance with the SEBI Guidelines for Preferential Issue in lieu of 3.56 million unsubscribed warrants as on date. (b) Extraordinary General Meeting - An Extraordinary General Meeting of the Company has been proposed to be held on Wednesday, February 14, 2007 to get the approval of the shareholders in respect of Issue of warrants to Promoter(s)/Promoter Group(s)/Relatives of Promoters.12 Jan · Board meeting
Meeting of the Board of Directors is proposed to be held on Friday, January 19, 2007, to take on record the un-audited financial results of Orchid for the period from October 01, 2006 to December 31, 2006.